TIBA BIOTECH, LLC
Biotech · Private
mRNA vaccine against H7N9 influenza using proprietary non-LNP delivery platform (RNABL)
- Grants
- $4.2M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 29
- 3 granted · 26 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · RNA-based multi-antigen vaccine for SARS-CoV-2 | $278,957 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid response to pandemic influenza via multi-antigen RNA-based vaccine | $284,906 | |
| Federal grant | Department of Health and Human Services · Phase I · Low-dose RNA vaccine platform for tickborne flaviviruses | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid response to pandemic influenza via multi-antigen RNA-based vaccine | $966,637 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid response to pandemic influenza via multi-antigen RNA-based vaccine | $965,678 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid response to pandemic influenza via multi-antigen RNA-based vaccine | $965,715 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Delivery of Tumor Antigen esaRNA to the Spleen for Cancer Immunotherapy | $399,300 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2611 | VERAMORPH LLC | — | $262K |
| 2612 | XCELL SCIENCE, INC. | — | — |
| 2613 | AEROBYX, LLC | — | — |
| 2614 | TIBA BIOTECH, LLC | — | — |
| 2615 | HB THERAPEUTICS, INC. | — | — |
| 2616 | NuRevelation, LLC | — | $250K |
| 2617 | Impact Proteomics, LLC | — | $250K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Versatile Biodegradable Molecules As Nucleic Acid Carriersapplication
- Gene Delivery Agentsapplication
- Novel Methods To Enhance Gene Deliveryapplication
- Novel Gene Delivery Agentsgranted
- Nanoparticle Compositions Containing Sugar Functionalized Nucleic Acid Carriersapplication
- Nanoparticle Compositions Containing Sugar Functionalized Nucleic Acid Carriersgranted
- Dendritic Architectures As Nonviral Vectors In Gene Deliveryapplication
- Nanoparticle Compositions Containing Sugar Functionalized Nucleic Acid Carriersgranted
- Nanoparticle Composition For The Delivery Of Nucleic Acid Agentsapplication
- Carriers For Efficient Nucleic Acid Deliveryapplication
- Nanoparticle Compositions For Efficient Nucleic Acid Delivery And Methods Of Making And Using The Sameapplication
- Versatile Biodegradable Molecules As Nucleic Acid Carriersapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.